Colorectal cancer Flashcards

1
Q

Epidemiology

A

3rd most common cancer in men/women

More young individuals being diagnosed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathophysiology

A

Malignant polyps grow from the inner basement membrane of the bowel wall outward into the muscosa, submucosa, muscularis, and serosa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

History of disease

A

Metastasis: bone, lungs, liver, lymph nodes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Risk factors

A

Age
Family hx
Familial Adenomatous Polyposis (FAP)
Hereditary Nonpolyposis colorectal cancer (HNPC)
Diet
Lifestyle
Polyps
Ulcerative colitis or Crohn’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Familial Adenomatous Polyposis (FAP)

A

Autosomal dominant: mutation of adenomatous polyposis coli on chromosome 5

Result: 100% of adenomatous polyps
Result: 100% of developing colon cancer by age 40
Solution: colectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Hereditary Nonpolyposis Colorectal Cancer

A

Autosomal dominant

80% risk of developing colon caner + other tumors (endometrial, stomach, ovarian)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Genetics

A

dMMR: defective mismatch pair

MSI: micro satellite instability

MSI-L=low level micro satellite instability
MSI-H= high level micro satellite instability

If stage 2 + dMMR/MSI-H–> no chemo
If stage 3 + dMMR/MSI-H–> chemo

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Signs/symptoms

A

Rectal bleeding, anemia, N/V, weight loss, change in bowel habits

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Presentation

A

20-25% of patients will present with metastatic disease: jaundice, hepatomegaly, weight loss

50-60% of patients diagnosed with colorectal cancer will develop metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Fecal occult blood test (FOBT)

A

Avoid false positives: no red meat, raw vegetables for 3 days prior to testing

Avoid false negatives: no vitamin C more than 250 mg for 3 days prior to testing

Medical restrictions:
Avoid enemas, rectal meds, and digital rectal exams
Avoid ASA and NSAIDS for 7 days prior to testing
Avoid testing if hemorrhoids
3 days after menstrual bleeding ended

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Fecal immunohistochemical test (FIT)

A

Detects hemmoglovin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

FIT DNA

A

Detects hemoglobin + DNA biomarkers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When to start screening?

A

Normal: 45 yo
Annual FOBT or FIT
Colonoscopy every 10 years

Family history: 40 yo or 10 years younger than youngest age of diagnosis in family

FAP: 10-12 yo

HNPCC: 20-25 yo or 10 years younger than youngest person of diagnosis in family

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Prevention

A

Diet: low fat, high fiber, high calcium

NSAIDS/ASPIRIN

Colectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment options

A

Surgery: early stage disease

Chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

FOLFOX

A

Requires port (implantable access device)

2-day pump

More infusions overall

17
Q

CapeOX

A

No port

Less infusions overall

Pearls: renal dose adjustments, drug-drug interactions

18
Q

Stage I and II

A

Surgery

If high risk stage II–> may consider chemo

CHECK dMMR-MDI-H–> if high, no chemo

FOLFOX: 5-FU + leucovorin + oxaliplatin

CapeOX: Capecitabine + Oxaliplatin

19
Q

Stage III

A

Surgery + chemo

FOLFOX
- 5-FU (bolus after leucovorin on day 1) + leucovorin + Oxaliplatin on day 1–> 5-FU continuous infusion x 2days every 14 days

Low risk: 3-6 months
High risk: 6 months

CapeOX
-Capecitabine x 14 days + Oxaliplatin on day 1 every 21 days

Low risk: 3 months
High risk: 3-6 months

20
Q

Stage IV 1st line (no mutations)

A

FOLFOX +/- Bevacizumab
CapeOX +/- Bevacizumab
FOLFIRI +/- Bevacizumab
FOLFIRINOX +/- Bevacizumab

21
Q

Stage IV 1st line KRAS wild type

A

FOLFOX/CapeOX + Cetuximab/Panitumumab

22
Q

Stage IV 1st line dMMR/MSI-H

A

FOLFOX/CapeOX THEN
pembrolizumab/nivolumab/ipilimumab

23
Q

Stage IV 1st line HER2+

A

Trastuzumab + pertuzumab/lapatinib
Trastuzumab/Deruxtecan

24
Q

Stage IV 2nd line

A

If previously received Oxaliplatin: FOLFIRI

If previously received Irinotecan: FOLFOX OR CapeOX

25
Q

Considerations in Chemo regimen for Colorectal cancer

A

Poor performance status

Other comorbidities:
-Neuropathy–> fewer platinum drugs
-UGT1A1 deficiency–> no irinotecan

PDL-1 status:
-dMMR/MSI-H–>pembrolizumab or nivolumab given after FOLFOX or CapeOX

KRAS: mutations predict lack of response to EGFR antibodies
-If positive–> no cetuximab or panitmumab

BRAF